When MRNA reports third-quarter earnings, investors will likely focus on the sales performance of its recently approved RSV ...

Learn about Moderna's Q3 earnings results, analysts' expectations, and RBC Capital Markets' outlook for the biotech company ...

Evercore ISI analyst Cory Kasimov lowered the firm’s price target on Moderna (MRNA) to $60 from $105 and keeps an In Line rating on the ...

SHELTON, CT / ACCESSWIRE / November 4, 2024 / NanoViricides, Inc. (NYSE American:NNVC) (the 'Company'), a clinical stage global leader in ...

Welcome to the Moderna third quarter 2024 conference call. [Operator instructions] Please be advised today's conference is ...

NanoViricides (NYSE American: NNVC) will present a corporate update at the Spartan Capital Investors <a target=_blank href= ...

Ducati debuted the biggest update for the Panigale V4 just months ago, while BMW recently revamped the S 1000 RR with some nitty-gritty yet crucial changes. Keeping the trend going now is Noale-based ...

As we head into RSV (respiratory syncytial virus) season, the risk of severe infection becomes a concern, especially for ...

NanoViricides, Inc. (NYSE Amer.: NNVC ) (the “Company”), a clinical stage global leader in broad-spectrum antiviral ...

This treatment enhances babies' immunity against RSV, a virus that poses a serious threat to infant ... including three ...

Innovative Surgical Techniques Used in World’s First Combined Face and Whole-Eye TransplantationAn explanation of how an NYU ...

EvolutionaryScale can design proteins with desired properties according to prompts by simultaneously evolving sequence, ...